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The randomised, double blind and placebo-
controlled trial by McGrath et al.1 concerning immune
modulation therapy (IMT) for the treatment of inter-
mittent claudication (IC) is interesting because of the
huge placebo response that was achieved. The
authors, however, have failed to comment on this or
to offer an alternative hypothesis. They prefer to
report their results as an improvement to walking
distance attributable to an immune response, although
they offer no biological evidence from their study to
support this.
Other features of the paper raise fundamental
concerns which need to be addressed. The choice of
placebo given to the control group severely weakens
this study. We would argue that untreated venous blood
should have been used rather than saline in the con-
trol group. In essence the treatment group has been
given a series of gluteal haematomas (albeit modified
by heat, light and ozone) during the treatment period,
whereas the control group was injected with saline
that would be rapidly absorbed after injection. As a
haematoma takes time to be broken down and causes
a more prolonged degree of discomfort, the different
results obtained in this study might be explained
purely on this difference alone. Indeed the authors
do not offer any immunological or haemodynamic
data whatsoever from their study to support their
hypothesis that the improved walking distance in the
multiple haematoma group is due to immune mod-
ulation and improvements to microcirculatory flow.
Could the authors clarify whether both groups were
told at baseline that further injections would be given
if there was no increase in their ICD? Were the patients
told specifically which element was the primary end
point or at what percentage increase in baseline ICD
that it would be triggered? Do the authors not think
that the placebo response from a more painful series
of injections (modified haematoma group) is therefore
likely to be far greater than that from those that were
less painful; i.e. a group told they would receive1078±5884/02/050466 05 $35.00/0 # 2002 Published by Elsevier Sc12 gluteal injections and then be treated with more if
their ICD had not improved are likely to simply try
harder on a treadmill test than they did at baseline.
The gluteal haematomas are likely to stimulate this
increased effort to an even greater degree than gluteal
saline. After 24 haematomas over a period of 12 weeks
the results obtained may simply illustrate the variabil-
ity that can be obtained in treadmill assessed ICD with
different types of placebo.
This hypothesis that the results of this study are
purely placebo generated (in both groups) is
supported by other data in the study:
 In their power calculation it was estimated that the
placebo response from the study would be just 10%,
but it was actually over 4 times greater than this.
Could the authors, therefore comment on the 44%
increase in ICD observed in their control group?
This was achieved despite a familiarisation with
up to 4 treadmill tests. How does this compare to
other placebo-controlled studies in the literature?
 In this study the ICD improved out of proportion to
the maximum walking distance (MWD). Why did
the authors chose the ICD as their primary end
point in preference to the MWD? Do the authors
not feel that the ICD is an end point that the patient
can more easily vary (as part of a placebo response)
during a treadmill test in comparison to the MWD?
Why was just a 50% increase in ICD chosen as the
cut-off to represent a response?
 Do the authors acknowledge that the giving of
uncomfortable injections may precipitate the desire
of a patient to walk for longer on a treadmill before
reporting the onset of pain since the patient knows
that this will both please the researcher and may
terminate the giving of a further series of injections?
The methodology by which 28% of the IMT group and
20% of the placebo group that were recruited into the
study only to be subsequently excluded from the final
analysis (Fig. 1 in the paper) requires further clarifica-
tion. In particular how does the exclusion from the
final analysis of 21% of the intention to treat patientsience Ltd
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Author's Reply
We thank Mr Turton and colleagues for their interest
in our study. Taking their points in turn:
Huge placebo response
We acknowledge that the immediate response seen
here in the placebo group is high, although to charac-
terise it as huge is to overstate the case. Placebo
responses as high as 36% have been reported in trials
of Pentoxifylline.1 Additionally, in a study comparing
Beraprost sodium to placebo, Michel Lievre et al.
reported that 42.2% of patients in the placebo group
Correspondence 467in the IMT group accord with the CONSORT2 guide-
lines?
In their introduction, they comment that `` many
pharmacological treatments have been tried for IC
though without major benefit'', however, Beebe,
et al.,3 discussed the doubling of MWD obtained at
24 weeks with Cilostazol. In their study, the authors
reported that IMT only improved MWD by a half ± a
result that was not statistically significant. But in their
conclusions they state that the increases in walking
distance with IMT are significant and that it is an
effective treatment for patients with IC. However,
taking p5 0.05 as the level of significance for their
primary end point there was no statistically signi-
ficant difference between the two groups in terms of
number of responders, or improvement to MWD.
Furthermore, the lack of benefit obtained in this
study with IMT or placebo to increase MWD (50 and
30% respectively) should be contrasted to the 122%
increase in MWD that is seen with supervised
exercise training as reported in the meta-analysis by
Gardner et al.4
The authors have also been positively selective in
their interpretation of data in the literature regarding
IMT; several of their references relate to abstracts and
the paper by Cooke et al.5 showed that there was no
statistically significant improvement in blood flow
parameters with IMT.
Could the authors provide details as to the homo-
geneity of the two groups during the study? E.g. How
many patients in each group changed their smoking
habits, cholesterol and antihypertensive medication,
exercise habits, diet, or body weight during the
6-month period of study, all of which could have
influenced the results independently of the IMT
received? Small changes in body weight for example
candramatically influencewalking distance.6 Although
the authors report a change in quality of life (QOL)
during the study, we would be grateful to know what
the baseline QOL domain scores were in each group
and whether they were the same in both groups?
The generalizability of these results to the general
population of claudicants seen in hospital is uncertain.
Did randomisation follow the COSORT2 guidelines?
Only 46 claudicants were recruited by each centre
over a period of 28 months which suggests that either
a great deal of patients were deemed not suitable for
inclusion or that there was a process of selection. The
adequacy of randomization is also difficult to ascer-
tain from the details provided in the paper. The treat-
ment to which the patient was randomized should
ideally be implemented by using allocation conceal-
ment to prevent prior knowledge of treatment assign-
ment. This shields those who enrol participants frombeing influenced by this knowledge. The decision to
enrol or reject a patient should be made, and informed
consent should be obtained from the participant, in
ignorance of the next assignment in the sequence.
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